Abstract
Brain degenerative disorders such as Alzheimer’s disease (AD) can be exacerbated by aberrant metabolism. Supplementation with probiotic bacteria is emerging as a promising preventative strategy for both neurodegeneration and metabolic syndrome. In this study, we assess the impact of the Lab4b probiotic consortium on (i) cognitive and pathological markers of AD progression and (ii) metabolic status in 3xTg-AD mice subjected to metabolic challenge with a high fat diet. The group receiving the probiotic performed better in the novel object recognition test and displayed higher hippocampal neuronal spine density than the control group at the end of the 12 weeks intervention period. These changes were accompanied by differences in localised (brain) and systemic anti-inflammatory responses that favoured the Probiotic group together with the prevention of diet induced weight gain and hypercholesterolaemia and the modulation of liver function. Compositional differences between the faecal microbiotas of the study groups included a lower Firmicutes:Bacteroidetes ratio and less numbers of viable yeast in the Probiotic group compared to the Control. The results illustrate the potential of the Lab4b probiotic as a neuroprotective agent and encourage further studies with human participants.
Introduction
The gut microbiota is a complex community of microorganisms heavily influenced by host genetics, diet and the environment and has a major impact upon host physiology (). A bidirectional communication pathway exists between the gut microbiota and the central nervous system (CNS), termed the “gut-microbiota-brain axis,” and there is increasing evidence linking disruptions of this pathway with neurological disease development (). It is emerging that neurodegenerative conditions such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) are associated with perturbations to the gut microbiota (; ).
AD is the most common form of dementia with estimates of 850,000 sufferers in the United Kingdom alone () and over 50 million worldwide (). AD is characterised by progressive loss of cognitive function and is thought to be driven, at least in part, by inflammatory damage and the deposition of amyloid beta (Aβ) plaques in the cortex and hippocampal regions of the brain leading to progressive synaptic loss and neuronal death (). Ageing is the strongest risk factor for AD and there is currently no cure for established disease, only strategies to slow progression and alleviate symptom severity (). Other risk factors for AD include the impact of metabolic syndrome and excess body weight during early/mid-life that has been shown to double the risk of developing AD during later life (). Numerous studies have shown that diet-induced obesity in genetically modified amyloid precursor protein mice leads to accelerated disease progression (; ; ) and with the increasing prevalence of obesity in society () there is a need for strategies to reduce excessive body weight gain as a means of reducing the risk of AD.
Probiotics are becoming recognised for their ability to impart immunological and metabolic benefits (including weight loss) on the host () and there is growing support for the use of probiotic supplementation to attenuate/prevent AD pathology in AD mice (, , ; ) and humans (). The Lab4b consortium, which comprises Lactobacillus paracasei, Lactobacillus salivarius, together with two strains of bifidobacteria, can enhance the immune responses in macrophages () and illicit protective effects in response to neuronal oxidative stress (). In the current study, we tested the hypothesis that the Lab4b probiotic would support cognitive function, ameliorate neurodegeneration, and improve metabolic status in metabolically challenged 3xTg-AD prone mice.
Materials and Methods
Reagents
All reagents were purchased from Sigma-Aldrich/Merck (Poole, United Kingdom) unless otherwise stated.
Ethics
Mouse experiments were performed under the United Kingdom Home Office Project Licence (PPL 30/3220). The 3xTg-AD mice were produced from an in-house colony, founders originally purchased from JAX laboratories (Bar Harbor, ME, United States, strain 004807) after generation by Frank LaFerla (University of California, Irvine).
Mouse Husbandry and Study Design
Twenty 3xTg-AD male mice were fed standard chow diets, ad libitum (Teklad rodent diet, Envigo) until 12 weeks of age before they were randomly assigned to two groups (10/group); one group received high fat diet alone for 12 weeks (termed the “Control” group) and the second group received HFD supplemented with the Lab4b probiotic providing a minimum of 5 × 108 colony forming unit (cfu)/mouse/day for 12 weeks (termed the “Probiotic” group). Mice were housed in scantainer vented cages (2–4 mice per cage) in a light and temperature-controlled environment (12 h on/off light at 22°C) and had ad libitum access to all diet and water. The HFD was provided to promote AD pathologies in these mice (; ; ) and comprised 21% (w/w) pork lard with 0.15% (w/w) cholesterol (Special Diets Services, Witham, United Kingdom; product code: 821424). Full dietary composition of both the chow and HFD are shown in Supplementary Tables 1, 2. Typically, male 3xTg mice display cognitive deficits from 2 months of age () and amyloid deposition in the brain from 6 months of age (). The Lab4b probiotic was administered by mixing with feed and comprised Lactobacillus salivarius CUL61 (NCIMB 30211), Lactobacillus paracasei CUL08 (NCIMB 30154), Bifidobacterium bifidum CUL20 (NCIMB 30153), and Bifidobacterium animalis subsp. lactis CUL34 (NCIMB 30172). Mice were weighed every 2 weeks over the duration of the intervention period. Mice were routinely screened for health over the duration of the study and no indications of infection or poor health were observed.
Sample Collection
At the end of the study, faecal samples were collected and stored in anaerobic bags (Genbag, bioMérieux) at −80°C. The mice were euthanised by CO2 inhalation and whole blood was obtained by cardiac exsanguination into heparinised tubes, centrifugation at 3,000 × g for 5 min and collection of plasma. The brain was removed by dissection and the right hemisphere was fixed in 4% paraformaldehyde (for histology) or analysed immediately for hippocampal slices (DiOlistic neuronal labelling). The left hemisphere of the brain was extracted and snap-frozen in liquid nitrogen (for RNA isolation and gene expression analyses). Whole livers were extracted, snap-frozen in liquid nitrogen and stored at −80°C (for RNA isolation, gene expression, and metabolite analyses).
Behavioural Testing
All behavioural testing was performed in a custom-made plastic test arena [39 cm (height) × 39 cm (width) × 39 cm (length)] placed in a class II laminar flow hood. The base of the arena was covered in a thin layer of wood chip sawdust. Novel object recognition (NOR) testing was performed in three stages spanning 2 days. On day 1, each mouse was allowed to explore the empty test arena for 10 min (habituation phase) before being returned to its normal housing. The next day, the mouse was placed in an empty arena for 10 min (open field test) before returning to its normal housing for 30 min. It was then placed back in the test arena along with two identical objects for 10 min (training phase) before being returned to its normal housing for 30 min followed by a further 10 min in the test arena containing a novel object in place of one of the identical objects (test phase). Results were expressed as the discrimination ratio (DR) calculated by dividing the time spent exploring the novel object (head oriented toward and within 2 cm) by the time spent exploring the familiar object plus the novel object. A reduction in DR denotes decreased preference and perception of a novel object and therefore an indicator of impaired memory. Mouse movements were recorded using a GoPro HERO session camera (GoPro, United States) positioned directly above the test arena and movements analysed using EthoVision XT 13 software (Noldus, Netherlands). The familiar and novel objects were similar in size but differed in colour and shape. Objects were rubbed with the cage sawdust to mask any potential scent from them and encourage the test to be more driven by visual awareness. The experimenter was blinded to the group allocation during the test.
Hippocampal Dendritic Spines
Hippocampal slices (right brain hemisphere) were subjected to DiOlistic gene gun labelling to assess the density of dendritic spines on CA1 apical dendrites according to a previous described method (; ). Bullet preparation: Briefly, the fluorometric dyes DiI (Life Technologies, United States) were dissolved in dichloromethane to coat tungsten particles (Bio-Rad, United States). DiI coated tungsten particles were funnelled into ethylene tetrafluoroethylene (ETFE) tubing for ballistic DiOlistic labelling of the hippocampal slices (200 μm thick). Slices were subjected to 100 psi particle delivery using a Helios Gene Gun (Bio-Rad, United States) through a 3.0 μm pore size cell culture insert. Prevention of over labelling and aggregated particles was minimised by frequent replacement of inserts. Hippocampal slices were placed in Neurobasal-A media (Life Technologies, United States) and incubated for 20 min at 37°C with 5% CO2 to facilitate dye diffusion. Slices were fixed in 4% paraformaldehyde (PFA) for 30 min at room temperature, nuclear stained with Hoechst 33342 and mounted in FluorSave. Spine imaging: DiI labelled CA1 neurones were imaged for their dendritic spines on apical dendrites within the striatum radium region using the Leica SP8 laser-scanning confocal microscope with lightning deconvolution (Leica Microsystems, Germany). Dendritic segments longer than 30 μm were 3D reconstructed using the Filament Tracer module in Bitplane Imaris software v9.3.1 and spines subtyped with the Spine Classifier MATLAB extension. Spines were morphologically classified based on predetermined settings as follows: spines <0.8 μm: stubby, >0.8 but <3 μm and with a spine head diameter greater than neck width: mushroom spines; other spines >0.8 but <3 μm: thin spines. Each reconstructed dendrite segment was manually checked to ensure correct spine detections. Each type of spine was averaged from at least three separate values from each mouse.
Brain Histology
The right brain hemisphere was fixed in 4% (w/v) PFA for ≥24 h before immersion in 30% (w/v) sucrose solution for up to 72 h. The brains were then placed in moulds with Optimal Cutting Temperature (OCT) Embedding Matrix (CellPath, United Kingdom) and frozen in dry ice and stored at −80°C prior to sectioning. Sections were cut at on a sagittal plane using a Cryostat (10 μm), mounted onto slides (X-tra Slides, Leica Biosystems) and stored at −80°C prior to staining.
For staining, sections were briefly exposed to citrate-based heat-induced antigen retrieval before immersion in BLOXALL solution (SP-6000, Vector Laboratories, Oxford, United Kingdom) for 10 min at room temperature (RT) followed by 30 min in 2.5% (v/v) normal horse serum at room temperature (S-2000, Vector Laboratories, Oxford, United Kingdom). Primary ionised calcium-binding adaptor protein-1 (Iba-1) antibody (Wako, Japan) was diluted 1:1000 in 2.5% (v/v) horse serum in PBS and incubated overnight at 4°C. Slides were stained with secondary species-specific biotinylated antibodies (Vector Laboratories, Oxford, United Kingdom) followed by the VECTASTAIN Elite ABC-HRP Kit (PK-6100, Vector Laboratories, Oxford, United Kingdom), and finally, ImmPACT Diaminobenzidine (DAB) Peroxidase (HRP) Substrate (Vector Laboratories, Oxford, United Kingdom) in accordance with the manufacturer’s instructions. Sections were then counterstained using haematoxylin, dehydrated in graded alcohols and cleared in xylene followed by DPX mounting under coverslips. Slides were scanned using the Axio Scan.Z1 Digital Slide Scanner (Carl Zeiss Ltd., United Kingdom) and analysis of the cortex and hippocampus was performed using QuPath (). Analysis was performed on one brain section per mouse.
For detecting and quantifying the density of amyloid plaques, cryosections were stained with Thioflavin S solution. Briefly, slides were air-dried and stained with filtered (0.2 μm) 0.1% Thioflavin S solution in 70% (v/v) ethanol for 10 min. After brief washes in 70% (v/v) ethanol, 50% (v/v) ethanol and water, the slides were cover slipped in FluorSave. Plaques coverage in the hippocampus and cortex were imaged using a Leica SP8 confocal microscope (Leica Microsystems, United Kingdom) and analysed in Bitplane Imaris software v9.3.1 using the volume function.
Tissue Extraction of RNA
Brain (left hemisphere) and liver tissues were homogenised with RiboZol (VWR, United States) for 3 × 20 s in a Fast Prep-24 Bead Beater (MPBIO, United States) with cooling on ice between each round. The homogenised tissues were extracted with chloroform and centrifuged at 12,000 g for 15 min at 4°C. The aqueous phase was extracted with isopropanol and centrifuged at 12,000 g for 10 min at 4°C. The RNA pellets were washed three times with ethanol (75% v/v), resuspended in RNAse free double-distilled (ddH2O) and quantified by Qubit (Thermo Fisher Scientific, United States).
Reverse Transcriptase Quantitative Polymerase Chain Reaction of Whole Tissue Extracts
cDNA was prepared from the RNA using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, United States) in accordance with the manufacturer’s instructions. cDNA (10 ng) was added to each qPCR reaction comprising iTaq™ Universal SYBR® Green Supermix (Applied Biosystems, United States) and 50 nM of each gene-specific primer (Supplementary Table 3). PCR was carried out on a CFX96 (Bio-Rad, United States) using the following cycles parameters: Initial melting (95°C for 5 min) followed by 40 cycles of melting (94°C for 15 s), annealing (60°C for 15 s), and extension (72°C for 30 s). Relative transcript levels were determined using 2-(ΔCt1–ΔCt2) where ΔCt represents the difference between the threshold cycle (Ct) for the target gene and β-actin transcript levels and are expressed as a ratio of the Control group.
Plasma Lipid and Cytokine Profiling
Plasma levels of total cholesterol (TC), high-density lipoprotein (HDL) and low-density lipoprotein (LDL)/very low-density lipoprotein (vLDL) were assayed using the Cholesterol assay kit (Abcam, United Kingdom) according to manufacturer’s instructions. Plasma levels of triglycerides (TG) were assayed using the Triglyceride assay kit (Abcam) according to manufacturer’s instructions. The following cytokines: Interferon (IFN)-γ, interleukin (IL)-2, IL-4, IL-5, IL-6, IL-10, IL-1β, Keratinocyte chemoattractant/growth regulated oncogene (KC/GRO), tumour necrosis factor (TNF)-α were measured in plasma [MSD multiplex platform performed by Central Biotechnology Services (CBS), Cardiff].
1H NMR Spectroscopic Analysis of Tissue and Data Analysis
Samples preparation is described in detail in the Supplementary Methods. Sample analysis was performed as previously described () using a Bruker DRX 600 MHz spectrometer (Bruker, Rheinstetten, Germany).
Microbiome Analysis
DNA Extraction From Faeces and 16S rRNA Gene Sequencing
DNA was extracted from faeces using the QIAamp® Fast DNA Stool Mini Kit (Qiagen, Germany) according to the manufacturer’s instructions. Briefly, samples were homogenised in Matrix Lysing D tubes (MPBIO) and a FastPrep®-24 bead beater (MPBIO, United States). Eluted genomic DNA were quantified using a Qubit® (Thermo Fisher Scientific, United States) and normalised to 5 ng in tris-acetate-ethylenediaminetetraacetic acid (TAE) and stored at −20°C. Sample libraries were prepared following Illumina’s 16S Metagenomic Sequencing Library Preparation Protocol with the following modifications. First, V1–V2 regions of the 16S rRNA gene were amplified in addition to bifidobacteria sequences (). The index PCR were cleaned-up and normalised using the SequalPrep Normalization Plate Kit (Life Technologies, Paisley, United Kingdom). Sample libraries were quantified using the NEBNext Library Quant Kit for Illumina (New England Biolabs, Hitchin, United Kingdom). Sequencing was performed on an Illumina MiSeq platform (Illumina Inc., Saffron Walden, United Kingdom) using the MiSeq Reagent Kit v3 (Illumina) and paired-end 300 base pairs (bp) chemistry. Negative controls for the sequencing were reactions containing no template DNA. The positive control comprised the defined bacterial community MCM1 (composition in Supplementary Table 4). Paired-end 16S rRNA gene sequencing reads were trimmed, chimaera reduced and paired ends were merged using DADA2 () to obtain sequence variants which were aligned against the SILVA database to assign taxonomy ().
Analysis of the Bacterial Composition in Faeces Using Next Generation Sequencing Data
Alpha (Chao1 and Shannon) and beta diversity measures were obtained in the R package “phyloseq” (). Weighted UniFrac matrix (with 10,000 permutations) () were calculated using the Adonis function of the R Vegan package ().
Ex vivo Culture of Viable Micro-Organisms in Faeces
Numbers of viable lactobacilli, enterobacteria, enterococci, coliforms, staphylococci, yeast, bifidobacteria, bacteroides, clostridia, total aerobes and total anaerobes were enumerated on selective media in accordance with a previously described method ().
Statistical Analysis
All statistics were performed using GraphPad PRISM (version 8.2.1, CA, United States) or R package (Version 3.1.3) unless otherwise stated with p < 0.05 considered statistically significant.
Prior to statistical analysis, the data were tested for normality using the Shapiro–Wilk test and visual inspection of Q–Q plots. For comparisons between two groups, an unpaired student’s t-test was performed on normally distributed (Gaussian) data and an unpaired Mann–Whitney student’s t-test was performed where data was not normally distributed (non-Gaussian). For multiple comparison testing on normally distributed data with equal variance between groups (determined using the Brown–Forsythe test), one-way ANOVA with Holm–Sidak post hoc analysis was performed. For multiple comparison testing on normally distributed data with unequal variance between groups, a Brown-Forsythe adjusted one-way ANOVA with Dunnett’s post hoc analysis was performed.
1H NMR spectral data were analysed using multivariate statistical analysis methods including principal component analysis (PCA) and orthogonal signal correction-projection to latent structures-discriminant analysis (O-PLS-DA) in MATLAB version 2017b (MathWorks, United States).
For the 16S rRNA gene sequencing data, differences in the Chao1 and Shannon indices amongst groups (Control and Probiotic group) were analysed using the non-parametric Wilcoxon rank sum test. Spatial differences of the groups were observed with a non-metric multidimensional scaling (NMDS) plot. The permutational analysis of variance (PERMANOVA) was computed on the weighted UniFrac matrix using in the Adonis function of the R Vegan package (), with cage effect as a “strata” parameter. Differential abundance of Amplicon Sequence Variant (ASV) amongst groups was analysed using DESeq2 (), and visualised with pheatmap in R.
Results
Lab4b Improves Cognition and Inhibits Diet Induced Weight Gain
Tracking mouse movements during the NOR task (Figure 1Ai) allowed for the calculation of a discrimination ratio (DR) that is a measure of the animals’ propensity to explore the novel object over the familiar object. After dietary intervention, the DR of the Probiotic group (0.64 ± 0.03) was significantly higher (28%, p = 0.0127, Figure 1Aii) than the DR of the Control group. While this analysis included all animals (10 per group) irrespective of the total amount of time spent interacting with objects, sub-group analysis was also performed on animals with more prolonged interest in objects over the 10 min period (Supplementary Figure 1). Assigning a threshold of total object interest to (i) 10 s or more, or (ii) 20 s or more () reduced the number of animals which could be included in the analysis, however, still yielded a significant increase in NOR in the Probiotic group compared to the Control group (10 s interest or more: p = 0.0067, 20 s interest or more: p = 0.0343, Supplementary Figure 1). Tracking mouse movements during the open field test (OFT) did not reveal any statistically significant between-group differences in distance travelled, velocity, time spent in the arena perimeter, clockwise body rotations nor time spent digging/rearing after 12 weeks supplementation (Table 1).
FIGURE 1
TABLE 1
| After 12 weeks intervention | p value | ||
| Control | Probiotic | ||
| Total distance travelled (cm) | 1509.36 ± 182.10 | 1570.23 ± 199.17 | 0.7962 |
| Velocity (cm/s) | 2.52 ± 0.30 | 2.62 ± 0.33 | 0.7962 |
| Time spent in arena centre (s) | 69.39 ± 10.43 | 68.65 ± 16.99 | 0.9706 |
| Time spent in arena perimeter (s) | 530.74 ± 10.43 | 531.49 ± 16.97 | 0.9706 |
| Number of digging episodes (f) | 31.30 ± 3.39 | 28.50 ± 3.56 | 0.5760 |
| Number of rearings (f) | 16.90 ± 1.80 | 14.60 ± 2.46 | 0.4606 |
Open field testing.
Data represent the means ± SEM from nine mice per group. Values of p were determined using an unpaired student’s t-test. Where data was not normally distributed, Mann–Whitney t-tests were performed. cm, centimetres; s, seconds; f, frequency.
Measurement of body weight over the duration of the study revealed that the Probiotic group weighed 28.9% less than the mice in the control group after 12 weeks feeding (p < 0.0001, Figure 1Bi); pre-intervention weights (Day 0) were similar between groups (Control: 29.9 g ± 0.9, Probiotic: 27.6 g ± 0.6) whereas the final weights in each group were 48.8 g ± 2.9 in the control group and 34.7 g ± 1.3 in the Probiotic group (p < 0.0001). Both groups had gained significant amounts of weight over the duration of the study but rates of increase were lower in the Probiotic group (25.7% from Day 0 to Day 84, p = 0.0022, Figure 1Bii) than in the Control group (63.2% from Day 0 to Day 84, p = 0.0003). Statistically significant between-group differences were present after 6 weeks (42 days) supplementation and remained until the end of the study (Figure 1Bii).
Lab4b Supplementation Minimises the Loss of Thin Neuronal Spines in the Hippocampal CA1 Region
DiOlistic staining of the hippocampus (Figure 2Ai) revealed significantly higher (37%) total neuronal spine density in the Probiotic group compared to the Control group (Probiotic: 11.60/10 μm ± 0.78 vs. Control: 8.47/10 μm ± 0.26, p < 0.0001, Figure 2Aii). At the end of the intervention, 66% more thin spines were observed in the Probiotic group compared to the Control (5.45/10 μm ± 0.50 vs. 3.29/10 μm ± 0.18, p = 0.0043, Figure 2Aiii) but there were no between-group differences in stubby or mushroom spines. There were no differences in brain weights between groups at the end of the study (Figure 2B). The cortex or hippocampal CA1 regions of the brain were stained by immunohistochemistry for amyloid but plaque presence could not be detected (data not shown).
FIGURE 2
The Probiotic group had significantly higher mRNA levels of complexin-2 (CPLX2, 1.88-fold, p = 0.0004), glutamate receptor ionotropic AMPA type subunit 1 (GRIA1, 2.57-fold, p = 0.0014), and neuronal migration factor (NSMF, 2.020-fold, p = 0.0001) compared to the Control group. There were indications of higher levels of brain-derived neurotrophic factor (BDNF, 1.22-fold, p = 0.0513, Figure 2C) mRNA in the Probiotic group compared to the Control. The mRNA expression levels of other neurocognitive-related genes and markers of oxidative stress and apoptosis remained unchanged between the Control and Probiotic groups (Supplementary Table 5).
Lab4b Has No Impact Upon Immune Cell Composition in the Brain but Improves the Transcript Rates of Key Inflammatory Markers
Immunohistochemical staining for Iba-1 (Figure 3A) revealed no differences in the numbers of microglial cells/macrophages in the cortex and hippocampal regions of the brain between the treatment groups at the end of the study (Figures 3B,C), however, qPCR analysis of inflammatory markers showed that the expression of interleukin (IL)-10 mRNA was higher in whole brain extracts of the Probiotic group compared to the Control group (8.94-fold, p = 0.014, Figure 3D). The mRNA levels of IL-18 (61%, p < 0.0001), NLRP1a (56%, p = 0.0256), NLRP1b (59%, p = 0.0063), and caspase-1 (91%, p < 0.0001) were decreased in the Probiotic group compared to the control group whereas NLRC4 expression was increased (3.25-fold, p = 0.0076). The mRNA expression levels of other inflammatory genes did not differ between groups and are shown in Supplementary Table 5.
FIGURE 3
Lab4b Supplementation Alters Plasma Levels of IL-10, KC/GRO, and TNF-α
As seen in Table 1, at the end of the study, plasma levels of IL-10, KC/GRO, and TNF-α were significantly lower (53.5%, p = 0.0068, 43.8%, p = 0.0232, and 34%, p = 0.0167, respectively) in the Probiotic group compared to the Control group. No other significant changes were observed between groups.
Lab4b Supplementation Improves Plasma Lipid Profile and Modulates the Expression of Lipogenic Genes in the Liver
Probiotic supplementation reduced between-group levels of vLDL/LDL by over 20% (12.04 mg/dL for the Control group vs. 9.45 mg/dL for the Probiotic group, p = 0.0452, Table 2) but with no effect on TC, TG, or HDL.
TABLE 2
| After 12 weeks intervention | p value | ||
| Control | Probiotic | ||
| Cytokine/chemokine (pg/ml) | |||
| Interferon-γ | 0.20 ± 0.03 | 0.24 ± 0.03 | 0.3316 |
| Interleukin-1β | 1.59 ± 0.17 | 1.84 ± 0.36 | 0.5406 |
| Interleukin-2 | 0.73 ± 0.13 | 0.72 ± 0.13 | 0.9332 |
| Interleukin-5 | 5.12 ± 1.50 | 8.47 ± 2.42 | 0.2475 |
| Interleukin-6 | 24.18 ± 3.55 | 34.65 ± 10.44 | 0.9118 |
| Interleukin-10 | 117.90 ± 22.76 | 54.87 ± 9.53 | 0.0068 |
| Keratinocyte chemoattractant/growth regulated oncogene | 400.98 ± 87.76 | 225.42 ± 19.49 | 0.0232 |
| Tumour necrosis factor-α | 21.66 ± 2.30 | 14.29 ± 1.59 | 0.0167 |
| Plasma lipid (mg/dL) | |||
| Total cholesterol | 113.80 ± 9.00 | 96.92 ± 4.93 | 0.2110 |
| Very low-density lipoprotein/low density lipoprotein | 12.04 ± 1.09 | 9.45 ± 0.51 | 0.0452 |
| High-density lipoprotein | 37.90 ± 3.73 | 32.67 ± 1.99 | 0.2475 |
| Triglycerides | 51.14 ± 7.80 | 40.42 ± 8.31 | 0.3598 |
Plasma cytokine/chemokine and lipid concentrations.
Data represent the means ± SEM of single measurements performed on samples from 10 mice per group. Values of p were determined using an unpaired student’s t-test. When data were not normally distributed (Shapiro–Wilk test), Mann–Whitney t-tests were performed.
mRNA expression levels in the liver were higher for SREBP-2 (1.39-fold, p = 0.008, Figure 4A) in the Probiotic group and lower for CD36 (52%, p = 0.0077) and PPAR-γ (48%, p = 0.0118) when compared to the Control group. The expression of other lipogenic genes and markers of oxidative stress in the liver were not influenced by the probiotic (Supplementary Table 5).
FIGURE 4
Lab4b Supplementation Influences the Metabolic Profile of the Liver
OPLS-DA analysis of metabolite profiles of liver tissues showed significant changes and were predictive of groups (Q2Yhat = 0.61, R2Yhat = 0.98, p = 0.001, R2X = 0.36, Figure 4Bi). Concentrations of glucose, lactate, glutathione, glutamine, glycogen, betaine, AMP, and NAD+ were higher in the Control group while valine and an unknown metabolite were higher in the Probiotic group (Figure 4Bii). Analysis of samples extracted from the brain (hippocampi, cortex, and cerebellum), faecal samples and blood plasma yielded no significant findings (Supplementary Figure 2).
Lab4b Supplementation Impacts Upon the Composition of the Gut Microbiota
At the end of the study, no between-group differences in alpha diversity (Chao1 nor Shannon index) were observed (Figure 5A). Non-metric multidimensional scaling (NMDS) identified a trend toward a spatial separation between the Probiotic and Control groups at the end of the intervention period (p = 0.0605, 10,000 permutations; Figure 5B). The Firmicutes:Bacteroidetes ratio (F:B) was significantly lower in the Probiotic group compared to the Control group by end of the study (p = 0.0299, Figure 5C). No cage effects were observed during the study (data not shown).
FIGURE 5
Amplicon sequence variant (ASV) abundance identified enrichments in both treatment groups compared to baseline (Figure 6). Blast analysis of enriched ASVs found from Acetatifactor and Blautia genera were enriched in the Control group whilst in the Probiotic group, ASVs from Ligilactobacillus, and Bacteroides genera, along with Lachnospiraceae and Oscillospiraceae family were enriched.
FIGURE 6
Between-group comparisons of the number of viable bacteria cultured from faeces identified lower numbers of lactobacilli (p = 0.0016, Figure 7A), enterobacteria (p = 0.0001), coliforms (p = 0.0027) and yeast (p = 0.0033), and higher numbers of enterococci (p = 0.0010) in the Probiotic group compared to the Control group. Viable numbers of staphylococci, bifidobacteria, Bacteroides, clostridia, total aerobes and total anaerobes were similar between groups. Numbers of Firmicutes were estimated by combining numbers of Lactobacillus, Clostridia, Enterococcus and Staphylococcus with the numbers of Bacteroides represent Bacteroidetes and the F:B was found to be lower in the Probiotic mice compared to the Control group (Figure 7B), agreeing with the NGS outcomes (Figure 5C).
FIGURE 7
Discussion
Using a high fat diet to exacerbate pathological changes, inflammation and metabolic deficits in 3xTg-AD mice, we have demonstrated improvements in recognition memory and hippocampal spine density and a reduction in weight gain in response to supplementation with the Lab4b probiotic.
Behavioural analyses using Novel Object Recognition (NOR) revealed a significantly higher discrimination ratio (DR) in the Probiotic mice compared to Control mice indicating a beneficial impact upon recognition memory sensitivity (). Mouse behaviour remained similar between groups during open field testing that, as proposed by , verifies the outcomes of NOR testing by eliminating the possible influence of altered locomotion. The improvement in memory observed in the mice in the Probiotic group occurred alongside increased mRNA expression of several memory-related brain markers including BDNF, CPLX2, and GRIA1. BDNF is considered vital for the maintenance of neuronal function impacting upon learning and memory and reduced expression has been observed in the AD brain (). CPLX2 encodes a protein involved in neurotransmitter release whilst GRIA1 encodes an excitatory glutamate (AMPA) receptor and deficiencies in the expression of each have been detected in the AD brain (; ). These findings align with other studies showing that dietary combinations of lactobacilli and bifidobacteria can prevent cognitive decline in ageing rats (), AD mice () and in a human AD population ().
The loss of recognition memory sensitivity in 3xTg-AD mice has been linked to neurodegeneration in the hippocampus (; ; ), particularly the CA1 sub-region during early disease (), and significantly lower neuronal spine density was observed in the CA1 region of the hippocampus in the Control mice compared to the group receiving Probiotic indicating better neuronal health and spinal plasticity. The morphological subtyping of dendritic spines, particularly in relation to spine head size, correlates with the functional attributes of the synapse and reflects synaptic plasticity during memory and learning. Our data suggests that thin dendritic spines, but not stubby or mushroom, are amenable to preservation with probiotic supplementation. Thin spine subtypes are highly motile spines crucial for activity-dependant formation and strengthening of synapses capable of expansion during learning. The preferential loss associated with thin spines are associated with deficits in spatial learning and memory, and a feature linked with neurodegenerative diseases and normal ageing ().
In support of these findings, we observed higher transcript levels of NSMF, a regulator of the DNA repair response (), and BDNF that is involved in neuronal survival in the whole brain extracts of the mice receiving Lab4b to the Control group. A recent study of demonstrated the ability of another probiotic to increase spine densities in the cortex of 3xTg-AD mice. Our own studies have also shown beneficial effects of probiotics on neuronal health in vitro with Lab4b demonstrating an ability to prevent loss of viability in human SH-SY5Y neurones exposed to neurotoxic challenge (). In vivo the neurodegenerative process can result in brain shrinkage and, while no differences in brain weight were observed in the current study, other studies using a multi-strain probiotic have been shown to rescue brain weight and volume loss in 6-month old 3xTg-AD mice ().
Neuro-inflammation as part of the progression of AD () involves an influx/activation of microglial cells and macrophages in the brain () but no differences in cell numbers or microglial activation were observed in the cortical and hippocampal regions of the Probiotic mice in relation to the Control. The gene expression levels of inflammatory markers were assessed and there was less expression of IL-18, NLRP1a, NLRP1b, and Caspase-1 in the brains of Probiotic mice compared to the Control mice which we conclude shows an impairment of inflammasome activity in this group. Elevated transcript levels of the pro-inflammatory cytokines IL-18 and IL-1β have been observed in the brains of AD patients (; ) and the secretion of these cytokines is modulated by inflammasomes that are caspase-1 activating multi-protein complexes involved in the activation of the innate immune response and cell death via pyroptosis (). It is worthy of note that, contrary to expectation, the expression of NLRC4, an inflammasome component associated with the augmentation of neuro-inflammation and cognitive decline during AD (), was significantly higher in the probiotic fed mice compared to the control although elevations did not adversely affect the expressions levels of IL-1β and IL-8 in the whole brain extracts of these mice.
IL-10, an anti-inflammatory cytokine associated with the resolution of neuro-inflammation (), was higher in the Probiotic group compared to the Control group. The over expression of IL-10 in the brains of AD mice has been associated with improved cognitive performance () although the role of IL-10 during AD is both complex and contentious; IL-10 deficiency has also been shown to reduce disease pathology in AD mice ().
Changes in the levels of circulatory cytokines are often observed during AD () and metabolic disease () and higher levels of IL-10 were observed in the circulation of the Control mice compared to the Probiotic mice. As previously mentioned, IL-10 is generally considered to be anti-inflammatory and it is plausible that higher levels in the Control group form part of the host response to the overtly inflammatory systemic environment that was absent in the Probiotic mice. It has also been shown that, in some instances, elevated levels of IL-10 can hinder the resolution of inflammation and drive disease progression in murine models of AD () thus supporting the anti-inflammatory capability of the probiotic. A significant between-group reduction in the circulating levels of the pro-inflammatory cytokine, TNF-α and pro-inflammatory chemokine, KC/GRO, were observed at the end of the study in favour of the mice receiving Lab4b. Similar findings have been observed in healthy Wistar rats receiving a similar probiotic intervention ().
Obesity and high cholesterol increase the risk of development of AD (; ) and metabolic disease states such as cardiovascular disease (). Weight gain and circulating levels of LDL-cholesterol in the Probiotic group were lower than those of the Control group supporting the findings of our own previous study in HFD-fed wild-type C57BL/6J mice () and a recent study showing the hypocholesterolaemic effects of the SLAB51 multistrain probiotic in 3xTg-AD mice (). The liver is the master regulator of host metabolism [with dysfunction linked to the progression of AD ()] and higher hepatic transcript levels of CD36 and PPAR-γ were observed in the Control mice compared to the mice receiving probiotic. CD36 and PPAR-γ play key roles in lipid-homoeostasis and increased hepatic mRNAs have been associated with abnormal storage of fat and hepatic steatosis (; ). SREBP-2 plays a key role in the biosynthesis of cholesterol in the liver by regulating the expression of the cholesterol synthesising enzyme 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR; ). Lower SREBP-2 expression was observed in the Control group and the expression of HMGCR was 40% higher in the Probiotic group compared to the Control (non-significant, see Supplementary Table 5), possibly indicating the presence of a compensatory mechanism to normalise the Lab4b-mediated reduction in LDL-cholesterol levels (). NMR analysis highlighted significantly higher glycogen and glucose in the Control group compared to the Probiotic group suggesting a potential for the probiotic to impact upon glucose and insulin tolerance. There is a growing awareness that perturbations in glucose/insulin metabolism can contribute to the development of AD, such that AD has been branded “diabetes of the brain” (), and there is evidence supporting the anti-diabetic effects of probiotics ().
Metabolic disorders and AD are associated with perturbations of the gut microbiota (; ) and 16S rRNA gene sequencing of faecal DNA identified significant reduction in the Firmicutes:Bacteroidetes (F:B) ratio in the Probiotic group. A high (F:B) is a characteristic of obesity (), therefore these findings are consistent with the prevention of weight gain observed in these mice. BLAST analysis of enriched ASVs found the Blautia genera to be associated with the Control mice. The Blautia genus has been found to be associated with fat accumulation in humans and so this is consistent with the weight gain in these mice (). Within the Probiotic mice, Ligilactobacillus murinus, which has been shown to play a role in maintaining a healthy microbiota, was found to be more abundant. This suggests that the probiotic could be causing beneficial changes within the microbiome ().
Analysing the faecal microbiota using microbiological techniques to enumerate the selected populations; probiotic supplementation revealed significant reductions in lactobacilli, enterobacteria, coliforms and yeast, while an increase in the enterococcal component of the microbiota was observed. Enterobacteria are enriched during AD () and have been shown to drive disease progression in Drosophila (). It is emerging that commensal intestinal yeast (the gut mycobiome) can contribute to both the progression of AD () and HFD-induced obesity (). however, it remains unclear and more investigation is needed. Furthermore, no significant change in the relative abundance of the Lactobacillus genus was observed in the Probiotic group compared to the Control (data not shown), thus, the number of viable but non-culturable bacteria could be an influence (). Estimation of the F:B ratio from the ex vivo analysis of microbial numbers showed indication of a reduction in the Probiotic group compared to the Control group in alignment with the NGS data presented in Figures 5, and 6.
There are a number of limitations to our study: (i) The absence of a longitudinally chow-fed control group means we cannot confirm the detrimental effects of the HFD although this was not the key aim of the study and has been demonstrated on numerous occasions elsewhere (; ; ). (ii) We were unable to assess the impact of Lab4b on amyloid deposition due the absence of amyloid plaques (a hallmark of AD) in the brain tissue of our animals. There is some evidence that phenotypic loss that can occur during the generation of sublines of 3xTg-AD mice () or it is possible that the absence of plaque is linked to the relatively young age of the mice. (iii) Cognitive function was assessed using only the NOR test thus limiting our understanding of the effects of Lab4b supplementation to a single cognitive domain. More comprehensive analysis was unfortunately limited in the study due to the limited space available when carrying out behavioural analyses in class II laminar flow hoods. This meant that tests such as the Morris water maze could not be applied and even the commonly used Y-maze did not fit within the flow hoods that were available. These restrictions were necessitated by the conduct of the work in a facility used for immunological studies. Such work requires housing of experimental mice in scantainers and husbandry (changing bedding, food, etc.) being carried out in class II laminar flow hoods. A battery of tests are required in future work to fully assess the cognitive effects of Lab4b. (iv) The rates of food intake were not measured so it is unclear if the probiotic-mediated weight loss is due to changes in lipid metabolism and/or satiety. (v) Only one dose of Lab4b was tested so the observed effects may not be optimal; however, the dose was selected to reflect a realistic human equivalent dose ().
In summary, this 3-month study in 3xTg-AD mice receiving a high fat diet demonstrated the ability of the Lab4b probiotic to slow cognitive decline and the progression of AD pathology in the midst of metabolic challenge while imparting metabolic improvements including the limitation of weight gain and lowering of plasma lipids. These findings support the potential use of probiotic bacteria to impair the progression of AD and highlight a holistic capability for the attenuation of a number of metabolic risk factors of AD and other metabolic disease states. On the basis of these findings there is support for translation in future human studies.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The data presented in the study are deposited in the European Genome-Phenome Archive (EGA) repository, accession number PRJEB51991.
Ethics statement
The animal study was reviewed and approved by the Animal Welfare and Ethical Review Body (AWERB), Cardiff University. Written informed consent was obtained from the owners for the participation of their animals in this study.
Author contributions
TH, TW, DM, and SP were responsible for the design of the study. TW, RB, JK-S, AJ, ST, MG, JL, and JRM performed the experiments. GM, DJ, TW, and DM performed the data and statistical analyses. JEM, JRM, and MAG provided assistance and knowledge that was vital to the completion of the manuscript. DM, SP, TW, and DJ prepared the manuscript. All authors contributed to the review of the manuscript.
Funding
This study was funded by Cultech Ltd.
Acknowledgments
We would like to acknowledge the Division of Digestive Diseases at Imperial College London which received financial and infrastructure support from the NIHR Imperial Biomedical Research Centre (BRC) based at Imperial College Healthcare NHS Trust and Imperial College London, NIHR Imperial Biomedical Research Centre (RDA02), and National Institute for Health Research (CL-2019-21-002).
Conflict of interest
TW, GM, JK-S, AJ, DM, ST, DJ, and SP were employed by the Cultech Ltd. The funder had the following involvement in the study: the design of the study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnins.2022.843105/full#supplementary-material
References
1
AkbariE.AsemiZ.Daneshvar KakhakiR.BahmaniF.KouchakiE.TamtajiO. R.et al (2016). Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: a randomized, double-blind and controlled trial.Front. Aging Neurosci.8:256. 10.3389/fnagi.2016.00256
2
Alzheimer’s Society’s (2019). Alzheimer’s Society’s View on Demography.London: Alzheimer’s Society.
3
AndersonM. J. (2001). A new method for non-parametric multivariate analysis of variance.Austral Ecol.2632–46. 10.1111/j.1442-9993.2001.01070.pp.x
4
AnsteyK. J.CherbuinN.BudgeM.YoungJ. (2011). Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies.Obes. Rev.12e426–e437. 10.1111/j.1467-789X.2010.00825.x
5
AyrapetyanM.OliverJ. D. (2016). The viable but non-culturable state and its relevance in food safety.Curr. Opin. Food Sci.8127–133. 10.1016/j.cofs.2016.04.010
6
BakerL. M.DaviesT. S.MasettiG.HughesT. R.MarchesiJ. R.JackA. A.et al (2021). A genome guided evaluation of the Lab4 probiotic consortium.Genomics1134028–4038. 10.1016/j.ygeno.2021.08.007
7
BankheadP.LoughreyM. B.FernandezJ. A.DombrowskiY.McArtD. G.DunneP. D.et al (2017). QuPath: open source software for digital pathology image analysis.Sci. Rep.7:16878. 10.1038/s41598-017-17204-5
8
BelfioreR.RodinA.FerreiraE.VelazquezR.BrancaC.CaccamoA.et al (2019). Temporal and regional progression of Alzheimer’s disease-like pathology in 3xTg-AD mice.Aging Cell18:e12873. 10.1111/acel.12873
9
BillingsL. M.OddoS.GreenK. N.McGaughJ. L.LaFerlaF. M. (2005). Intraneuronal Abeta causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice.Neuron45675–688. 10.1016/j.neuron.2005.01.040
10
BinleyK. E.NgW. S.BardeY. A.SongB.MorganJ. E. (2016). Brain-derived neurotrophic factor prevents dendritic retraction of adult mouse retinal ganglion cells.Eur. J. Neurosci.442028–2039. 10.1111/ejn.13295
11
BonfiliL.CecariniV.BerardiS.ScarponaS.SuchodolskiJ. S.NasutiC.et al (2017). Microbiota modulation counteracts Alzheimer’s disease progression influencing neuronal proteolysis and gut hormones plasma levels.Sci. Rep.7:2426. 10.1038/s41598-017-02587-2
12
BonfiliL.CecariniV.CuccioloniM.AngelettiM.BerardiS.ScarponaS.et al (2018). SLAB51 probiotic formulation activates SIRT1 pathway promoting antioxidant and neuroprotective effects in an AD mouse model.Mol. Neurobiol.557987–8000. 10.1007/s12035-018-0973-4
13
BonfiliL.CecariniV.GogoiO.GongC.CuccioloniM.AngelettiM.et al (2020). Microbiota modulation as preventative and therapeutic approach in Alzheimer’s disease.FEBS J2882836–2855. 10.1111/febs.15571
14
BonfiliL.CuccioloniM.GongC.CecariniV.SpinaM.ZhengY.et al (2022). Gut microbiota modulation in Alzheimer’s disease: focus on lipid metabolism.Clin. Nutr.41698–708. 10.1016/j.clnu.2022.01.025
15
BroadbentN. J.GaskinS.SquireL. R.ClarkR. E. (2010). Object recognition memory and the rodent hippocampus.Learn. Mem.175–11. 10.1101/lm.1650110
16
CallahanB. J.McMurdieP. J.RosenM. J.HanA. W.JohnsonA. J.HolmesS. P. (2016). DADA2: high-resolution sample inference from Illumina amplicon data.Nat. Methods13581–583. 10.1038/nmeth.3869
17
CaoD. X.WongE. Y.VelaM. N.LeQ. T. (2021). Effect of probiotic supplementation on glycemic outcomes in patients with abnormal glucose metabolism: a systematic review and meta-analysis of randomized controlled trials.Ann. Nutr. Metab.77251–261. 10.1159/000518677
18
ChakrabartyP.LiA.Ceballos-DiazC.EddyJ. A.FunkC. C.MooreB.et al (2015). IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior.Neuron85519–533. 10.1016/j.neuron.2014.11.020
19
DabkeK.HendrickG.DevkotaS. (2019). The gut microbiome and metabolic syndrome.J. Clin. Invest.1294050–4057. 10.1172/jci129194
20
DaviesT.PlummerS.JackA.AllenM.MichaelD. (2018). Lactobacillus and Bifidobacterium Promote antibacterial and antiviral immune response in human macrophages.J. Probiotics Health6:195.
21
DumitriuD.HaoJ.HaraY.KaufmannJ.JanssenW. G.LouW.et al (2010). Selective changes in thin spine density and morphology in monkey prefrontal cortex correlate with aging-related cognitive impairment.J. Neurosci.307507–7515. 10.1523/JNEUROSCI.6410-09.2010
22
EstradaL. D.AhumadaP.CabreraD.ArabJ. P. (2019). Liver dysfunction as a novel player in Alzheimer’s progression: looking outside the brain.Front. Aging Neurosci.11:174. 10.3389/fnagi.2019.00174
23
FanY.PedersenO. (2020). Gut microbiota in human metabolic health and disease.Nat. Rev. Microbiol.1955–71. 10.1038/s41579-020-0433-9
24
GanW. B.GrutzendlerJ.WongW. T.WongR. O.LichtmanJ. W. (2000). Multicolor “DiOlistic” labeling of the nervous system using lipophilic dye combinations.Neuron27219–225. 10.1016/s0896-6273(00)00031-3
25
GlymenakiM.BarnesA.O’HaganS.WarhurstG.McBainA. J.WilsonI. D.et al (2017). Stability in metabolic phenotypes and inferred metagenome profiles before the onset of colitis-induced inflammation.Sci. Rep.7:8836. 10.1038/s41598-017-08732-1
26
GuarnerV.Rubio-RuizM. E. (2015). Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease.Interdiscip. Top. Gerontol.4099–106. 10.1159/000364934
27
Guillot-SestierM. V.DotyK. R.GateD.RodriguezJ.Jr.LeungB. P.Rezai-ZadehK.et al (2015). Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology.Neuron85534–548. 10.1016/j.neuron.2014.12.068
28
HemonnotA. L.HuaJ.UlmannL.HirbecH. (2019). Microglia in Alzheimer disease: well-known targets and new opportunities.Front. Aging Neurosci.11:233. 10.3389/fnagi.2019.00233
29
HoppertonK. E.MohammadD.TrepanierM. O.GiulianoV.BazinetR. P. (2018). Markers of microglia in post-mortem brain samples from patients with Alzheimer’s disease: a systematic review.Mol. Psychiatry23177–198. 10.1038/mp.2017.246
30
JohnA.ReddyP. H. (2020). Synaptic basis of Alzheimer’s disease: focus on synaptic amyloid beta, P-Tau and mitochondria.Ageing Res. Rev.65:101208. 10.1016/j.arr.2020.101208
31
JuM. K.ShinK. J.LeeJ. R.KhimK. W.LeeA. E.RaJ. S.et al (2021). NSMF promotes the replication stress-induced DNA damage response for genome maintenance.Nucleic Acids Res.495605–5622. 10.1093/nar/gkab311
32
JulienC.TremblayC.PhivilayA.BerthiaumeL.EmondV.JulienP.et al (2010). High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model.Neurobiol. Aging311516–1531. 10.1016/j.neurobiolaging.2008.08.022
33
KelleyN.JeltemaD.DuanY.HeY. (2019). The NLRP3 inflammasome: an overview of mechanisms of activation and regulation.Int. J. Mol. Sci.20:3328. 10.3390/ijms20133328
34
KimD.ChoJ.LeeI.JinY.KangH. (2017). Exercise attenuates high-fat diet-induced disease progression in 3xTg-AD mice.Med. Sci. Sports Exerc.49676–686. 10.1249/MSS.0000000000001166
35
KiyotaT.IngrahamK. L.SwanR. J.JacobsenM. T.AndrewsS. J.IkezuT. (2012). AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice.Gene Ther.19724–733. 10.1038/gt.2011.126
36
KnightE. M.MartinsI. V.GumusgozS.AllanS. M.LawrenceC. B. (2014). High-fat diet-induced memory impairment in triple-transgenic Alzheimer’s disease (3xTgAD) mice is independent of changes in amyloid and tau pathology.Neurobiol. Aging351821–1832. 10.1016/j.neurobiolaging.2014.02.010
37
KwilaszA. J.GraceP. M.SerbedzijaP.MaierS. F.WatkinsL. R. (2015). The therapeutic potential of interleukin-10 in neuroimmune diseases.Neuropharmacology9655–69. 10.1016/j.neuropharm.2014.10.020
38
LegerM.QuiedevilleA.BouetV.HaelewynB.BoulouardM.Schumann-BardP.et al (2013). Object recognition test in mice.Nat. protoc.82531–2537. 10.1038/nprot.2013.155
39
LissK. H.FinckB. N. (2017). PPARs and nonalcoholic fatty liver disease.Biochimie13665–74. 10.1016/j.biochi.2016.11.009
40
LiuP.WuL.PengG.HanY.TangR.GeJ.et al (2019). Altered microbiomes distinguish Alzheimer’s disease from amnestic mild cognitive impairment and health in a Chinese cohort.Brain Behav. Immun.80633–643. 10.1016/j.bbi.2019.05.008
41
LoveM. I.HuberW.AndersS. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.Genome Biol.15:550. 10.1186/s13059-014-0550-8
42
LozuponeC.KnightR. (2005). UniFrac: a new phylogenetic method for comparing microbial communities.Appl. Environ. Microbiol.718228–8235. 10.1128/AEM.71.12.8228-8235.2005
43
LuoJ.YangH.SongB. L. (2020). Mechanisms and regulation of cholesterol homeostasis.Nat. Rev. Mol. Cell Biol.21225–245. 10.1038/s41580-019-0190-7
44
McMurdieP. J.HolmesS. (2013). phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data.PLoS One8:e61217. 10.1371/journal.pone.0061217
45
MichaelD. R.DaviesT. S.LoxleyK. E.AllenM. D.GoodM. A.HughesT. R.et al (2019). In vitro neuroprotective activities of two distinct probiotic consortia.Benef. Microbes10437–447. 10.3920/BM2018.0105
46
MichaelD. R.DaviesT. S.MossJ. W. E.CalventeD. L.RamjiD. P.MarchesiJ. R.et al (2017). The anti-cholesterolaemic effect of a consortium of probiotics: an acute study in C57BL/6J mice.Sci. Rep.7:2883. 10.1038/s41598-017-02889-5
47
MirandaM.MoriciJ. F.ZanoniM. B.BekinschteinP. (2019). Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain.Front. Cell Neurosci.13:363. 10.3389/fncel.2019.00363
48
MoraisL. H.SchreiberH. L.IVMazmanianS. K. (2020). The gut microbiota-brain axis in behaviour and brain disorders.Nat. Rev. Microbiol.19241–255. 10.1038/s41579-020-00460-0
49
MoshkelgoshaS.MasettiG.Berchner-PfannschmidtU.VerhasseltH. L.HorstmannM.Diaz-CanoS.et al (2018). Gut microbiome in BALB/c and C57BL/6J mice undergoing experimental thyroid autoimmunity associate with differences in immunological responses and thyroid function.Horm. Metab. Res.50932–941. 10.1055/a-0653-3766
50
NagpalR.NethB. J.WangS.MishraS. P.CraftS.YadavH. (2020). Gut mycobiome and its interaction with diet, gut bacteria and Alzheimer’s disease markers in subjects with mild cognitive impairment: a pilot study.EBioMedicine59:102950. 10.1016/j.ebiom.2020.102950
51
NairA. B.JacobS. (2016). A simple practice guide for dose conversion between animals and human.J. Basic Clin. Pharm.727–31. 10.4103/0976-0105.177703
52
NessG. C.HollandR. C.LopezD. (2006). Selective compensatory induction of hepatic HMG-CoA reductase in response to inhibition of cholesterol absorption.Exp. Biol. Med.231559–565. 10.1177/153537020623100510
53
NguyenT. T.TaQ. T. H.NguyenT. K. O.NguyenT. T. D.GiauV. V. (2020). Type 3 diabetes and its role implications in Alzheimer’s disease.Int. J. Mol. Sci.21:3165. 10.3390/ijms21093165
54
OddoS.CaccamoA.ShepherdJ. D.MurphyM. P.GoldeT. E.KayedR.et al (2003). Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.Neuron39409–421. 10.1016/s0896-6273(03)00434-3
55
O’HaganC.LiJ. V.MarchesiJ. R.PlummerS.GaraiovaI.GoodM. A. (2017). Long-term multi-species Lactobacillus and Bifidobacterium dietary supplement enhances memory and changes regional brain metabolites in middle-aged rats.Neurobiol. Learn. Mem.14436–47. 10.1016/j.nlm.2017.05.015
56
OjalaJ.AlafuzoffI.HerukkaS. K.van GroenT.TanilaH.PirttilaT. (2009). Expression of interleukin-18 is increased in the brains of Alzheimer’s disease patients.Neurobiol. Aging30198–209. 10.1016/j.neurobiolaging.2007.06.006
57
OzatoN.SaitoS.YamaguchiT.KatashimaM.TokudaI.SawadaK.et al (2019). Blautia genus associated with visceral fat accumulation in adults 20–76 years of age.NPJ Biofilms Microbiomes5:28. 10.1038/s41522-019-0101-x
58
Perez-CruzC.NolteM. W.van GaalenM. M.RustayN. R.TermontA.TangheA.et al (2011). Reduced spine density in specific regions of CA1 pyramidal neurons in two transgenic mouse models of Alzheimer’s disease.J. Neurosci.313926–3934. 10.1523/JNEUROSCI.6142-10.2011
59
QiH.LiY.YunH.ZhangT.HuangY.ZhouJ.et al (2019). Lactobacillus maintains healthy gut mucosa by producing L-Ornithine.Commun. Biol.2:171. 10.1038/s42003-019-0424-4
60
QuastC.PruesseE.YilmazP.GerkenJ.SchweerT.YarzaP.et al (2013). The SILVA ribosomal RNA gene database project: improved data processing and web-based tools.Nucleic Acids Res.41D590–D596. 10.1093/nar/gks1219
61
RadaP.Gonzalez-RodriguezA.Garcia-MonzonC.ValverdeA. M. (2020). Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?Cell Death Dis.11:802. 10.1038/s41419-020-03003-w
62
RadiskeA.RossatoJ. I.GonzalezM. C.KohlerC. A.BevilaquaL. R.CammarotaM. (2017). BDNF controls object recognition memory reconsolidation.Neurobiol. Learn. Mem.14279–84. 10.1016/j.nlm.2017.02.018
63
Ramos-MiguelA.SawadaK.JonesA. A.ThorntonA. E.BarrA. M.LeurgansS. E.et al (2017). Presynaptic proteins complexin-I and complexin-II differentially influence cognitive function in early and late stages of Alzheimer’s disease.Acta Neuropathol.133395–407. 10.1007/s00401-016-1647-9
64
RossatoJ. I.BevilaquaL. R.MyskiwJ. C.MedinaJ. H.IzquierdoI.CammarotaM. (2007). On the role of hippocampal protein synthesis in the consolidation and reconsolidation of object recognition memory.Learn. Mem.1436–46. 10.1101/lm.422607
65
SaadiM.KarkhahA.PourabdolhosseinF.AtaieA.MonifM.NouriH. R. (2020). Involvement of NLRC4 inflammasome through caspase-1 and IL-1β augments neuroinflammation and contributes to memory impairment in an experimental model of Alzheimer’s like disease.Brain Res. Bull.15481–90. 10.1016/j.brainresbull.2019.10.010
66
Saiz-VazquezO.Puente-MartinezA.Ubillos-LandaS.Pacheco-BonrostroJ.SantabarbaraJ. (2020). Cholesterol and Alzheimer’s disease risk: a meta-meta-analysis.Brain Sci.10:386. 10.3390/brainsci10060386
67
SaresellaM.La RosaF.PianconeF.ZoppisM.MarventanoI.CalabreseE.et al (2016). The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease.Mol. Neurodegener.11:23. 10.1186/s13024-016-0088-1
68
SilvermanM. G.FerenceB. A.ImK.WiviottS. D.GiuglianoR. P.GrundyS. M.et al (2016). Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis.JAMA3161289–1297. 10.1001/jama.2016.13985
69
SivakumaranM. H.MackenzieA. K.CallanI. R.AingeJ. A.O’ConnorA. R. (2018). The discrimination ratio derived from novel object recognition tasks as a measure of recognition memory sensitivity, not bias.Sci. Rep.8:11579. 10.1038/s41598-018-30030-7
70
StojanovS.BerlecA.StrukeljB. (2020). The influence of probiotics on the firmicutes/bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease.Microorganisms8:1715. 10.3390/microorganisms8111715
71
SunM.BaoW.HuangC.XiaZ.ZhangC.WangG.et al (2021). Formula, BIOCG, protects against Alzheimer’s-related cognitive deficits via regulation of dendritic spine dynamics.Curr. Alzheimer Res.18558–572. 10.2174/1567205018666211022091110
72
SunS.SunL.WangK.QiaoS.ZhaoX.HuX.et al (2021). The gut commensal fungus, Candida parapsilosis, promotes high fat-diet induced obesity in mice.Commun. Biol.4:1220. 10.1038/s42003-021-02753-3
73
TanC.LiuY.ZhangH.DiC.XuD.LiangC.et al (2022). Neuroprotective effects of probiotic-supplemented diet on cognitive behavior of 3xTg-AD mice.J. Healthc. Eng.2022:4602428. 10.1155/2022/4602428
74
Tenorio-JimenezC.Martinez-RamirezM. J.GilA.Gomez-LlorenteC. (2020). Effects of probiotics on metabolic syndrome: a systematic review of randomized clinical Trials.Nutrients12:124. 10.3390/nu12010124
75
WalkerK. A.FicekB. N.WestbrookR. (2019). Understanding the role of systemic inflammation in Alzheimer’s disease.ACS Chem. Neurosci.103340–3342. 10.1021/acschemneuro.9b00333
76
WebberleyT. S.MasettiG.BakerL. M.DallyJ.HughesT. R.MarchesiJ. R.et al (2021). The impact of Lab4 probiotic supplementation in a 90-day study in Wistar rats.Front. Nutr.8:778289. 10.3389/fnut.2021.778289
77
WilliamsJ. B.CaoQ.YanZ. (2021). Transcriptomic analysis of human brains with Alzheimer’s disease reveals the altered expression of synaptic genes linked to cognitive deficits.Brain Commun.3:fcab123. 10.1093/braincomms/fcab123
78
World Health Organisation [WHO] (2018). Fact Sheet No 311: Obesity and Overweight.Geneva: World Health Organisation.
79
World Health Organisation [WHO] (2020). Fact Sheet on Dementia.Geneva: World Health Organisation.
80
WuS. C.CaoZ. S.ChangK. M.JuangJ. L. (2017). Intestinal microbial dysbiosis aggravates the progression of Alzheimer’s disease in Drosophila.Nat. Commun.8:24. 10.1038/s41467-017-00040-6
81
YiannopoulouK. G.PapageorgiouS. G. (2020). Current and future treatments in Alzheimer disease: an update.J. Cent. Nerv. Syst. Dis.12:1179573520907397. 10.1177/1179573520907397
82
ZhangF.YueL.FangX.WangG.LiC.SunX.et al (2020). Altered gut microbiota in Parkinson’s disease patients/healthy spouses and its association with clinical features.Parkinsonism Relat. Disord.8184–88. 10.1016/j.parkreldis.2020.10.034
83
ZhuG.ZhaoJ.ZhangH.ChenW.WangG. (2021). Probiotics for mild cognitive impairment and Alzheimer’s disease: a systematic review and meta-analysis.Foods10:1672. 10.3390/foods10071672
84
ZhuangZ. Q.ShenL. L.LiW. W.FuX.ZengF.GuiL.et al (2018). Gut microbiota is altered in patients with Alzheimer’s disease.J. Alzheimers Dis.631337–1346. 10.3233/JAD-180176
Summary
Keywords
Alzheimer’s disease, neurodegeneration, probiotics, microbiota, obesity, inflammation
Citation
Webberley TS, Masetti G, Bevan RJ, Kerry-Smith J, Jack AA, Michael DR, Thomas S, Glymenaki M, Li J, McDonald JAK, John D, Morgan JE, Marchesi JR, Good MA, Plummer SF and Hughes TR (2022) The Impact of Probiotic Supplementation on Cognitive, Pathological and Metabolic Markers in a Transgenic Mouse Model of Alzheimer’s Disease. Front. Neurosci. 16:843105. doi: 10.3389/fnins.2022.843105
Received
24 December 2021
Accepted
23 March 2022
Published
24 May 2022
Volume
16 - 2022
Edited by
Silvia Turroni, University of Bologna, Italy
Reviewed by
David Vauzour, University of East Anglia, United Kingdom; Claudia Perez-Cruz, Centro de Investigación y de Estudios Avanzados, Instituto Politécnico Nacional de México (CINVESTAV), Mexico
Updates
Copyright
© 2022 Webberley, Masetti, Bevan, Kerry-Smith, Jack, Michael, Thomas, Glymenaki, Li, McDonald, John, Morgan, Marchesi, Good, Plummer and Hughes.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Thomas S. Webberley, tomw@cultech.co.uk
This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.